|
TABLE 4 | ||||||||
|
REGENERON PHARMACEUTICALS, INC. | ||||||||
|
COLLABORATION AND OTHER REVENUE (Unaudited) | ||||||||
|
(In thousands) | ||||||||
|
Three Months Ended March 31, | ||||||||
|
2018 |
2017 | |||||||
|
Sanofi collaboration revenue: |
||||||||
|
Reimbursement of Regeneron research and development expenses |
$ |
134,218 |
$ |
213,924 |
||||
|
Reimbursement of Regeneron commercialization-related expenses |
86,634 |
73,559 |
||||||
|
Regeneron's share of losses in connection with commercialization of antibodies |
(74,874) |
(108,402) |
||||||
|
Other |
43,512 |
31,286 |
||||||
|
Total Sanofi collaboration revenue |
189,490 |
210,367 |
||||||
|
Bayer collaboration revenue: |
||||||||
|
Regeneron's net profit in connection with commercialization of EYLEA outside the United States |
232,068 |
174,876 |
||||||
|
Reimbursement of Regeneron development expenses |
3,997 |
6,349 |
||||||
|
Other |
11,863 |
12,714 |
||||||
|
Total Bayer collaboration revenue |
247,928 |
193,939 |
||||||
|
Total Sanofi and Bayer collaboration revenue |
$ |
437,418 |
$ |
404,306 |
||||
|
Other revenue: |
||||||||
|
Reimbursement of Regeneron research and development expenses - Teva |
$ |
39,129 |
$ |
22,050 |
||||
|
Reimbursement of Regeneron research and development expenses - other |
2,695 |
2,650 |
||||||
|
Other |
44,334 |
31,740 |
||||||
|
Total other revenue |
$ |
86,158 |
$ |
56,440 |
||||
